Separator

Accutest Biologics Receives GLP Certification; Leverages Growing Global Drug Demand

Separator
Si TeamOne of the leading Indian Contract Research Organizations, Accutest Biologics Private Limited (ABPL) received global honour with the OECD-Good Laboratory Practice (GLP) certification for the next three years. With this recognition, ABPL will improve the growing global demand for Biologics and Biosimilar drugs.

Dr. Satish Sawant, Founder & CEO, ABPL, comments, “The Navi Mumbai facility is capable of conducting toxicity studies, mutagenicity studies, analytical and clinical testing. This significant milestone enables us to advance as the global service provider living up to the biopharmaceutical industry expectations and maintaining high-quality deliverables”.

This significant milestone enables us to advance as the global service provider living up to the biopharmaceutical industry expectations and maintaining high-quality deliverables


Earlier this year, National Good Laboratory Practice Compliance Monitoring Authority (NGCMA) conducted a detailed pre-inspection at Navi Mumbai and ABPL received the GLP certification.
One of the leading Indian Contract Research Organizations, Accutest Biologics Private Limited (ABPL) received global honour with the OECD-Good Laboratory Practice (GLP) certification for the next three years. With this recognition, ABPL will improve the growing global demand for Biologics and Biosimilar drugs.

Dr. Satish Sawant, Founder & CEO, ABPL, comments, “The Navi Mumbai facility is capable of conducting toxicity studies, mutagenicity studies, analytical and clinical testing. This significant milestone enables us to advance as the global service provider living up to the biopharmaceutical industry expectations and maintaining high-quality deliverables”.

Earlier this year, National Good Laboratory Practice Compliance Monitoring Authority (NGCMA) conducted a detailed pre-inspection at Navi Mumbai and ABPL received the GLP certification. However, the industry expects Indian CRO Market to reach around $1 billion by 2023 with a CAGR of 12 percent. India is becoming a top destination because of its acceptance of international guidelines and intellectual property rights, presence of diverse types of climatic conditions thus allowing and more. In addition, CRO services market is valued at $36 billion in 2017 and projected to reach to $56 billion by 2023 with a CAGR of 7.6 percent.

“The certification places ABPL in the select league of CROs that have been awarded such a global honour. It is a matter of pride and privilege for ABPL not only to serve the biopharma industry with established credibility and also to get recognized in all the OECD member countries for mutual acceptance of the data,” comments, Dr. Mallikarjun Dixit, Test Facility Management, ABPL.

Established in 1998, Accutest Research Laboratories offers Phase II-IV clinical trials services for drug development companies in India and internationally. Accutest possess a large data bank of 41,000+ volunteers, 700+ validated methods along with strong records from major global regulatory agencies like USFDA, EMA, UK-MHRA, WHO, ANVISA (Brazil), MCC (South Africa) and MPRA (Malaysia).